Join Us for a Recurrent Pericarditis Free Educational Seminar June 26th, 7pm ET Click here to register.

FB Banner correct size

Test Title

Indication

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

Treatment of Recurrent Pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

Important Safety Information

ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret^® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel^® (etanercept), Humira^® (adalimumab), or Remicade^® (infliximab), as this may increase your risk of getting a serious infection.
Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
Medicines that affect the immune system may increase the risk of getting cancer.
Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.

For more information about ARCALYST, speak with your doctor and see the full Prescribing Information.

Follow us on Social Media:

This site is intended for US audiences only.

ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. All other trademarks and registered trademarks are the property of their respective owners.

Kiniksa OneConnect is a Trademark of Kiniksa Pharmaceuticals.

© 2025 Kiniksa Pharmaceuticals. All Rights Reserved. 5/25 ARC-US-00306-24

Terms of Use Privacy Policy Contact Us

Email Form

Facebook

This field is for validation purposes and should be left unchanged.

To

From

Subject

Message

Frequently Asked Questions

Who should attend?

This event is intended for the U.S. recurrent pericarditis community.

How do I register?

Complete the registration form and press “SUBMIT.” Once you have registered, you will receive a confirmation email with the event details.

Who can help me if I’m having difficulty with the online registration?

If you are having difficulty with the online registration, please email [email protected]

Is there a cost to attend?

No, there is no cost to attend this virtual event.

When should I arrive?

Please log on five minutes prior to the event start time.

How will I know how to log on to the webinars?

Pre-registration is required for the webinar. Prior to the webinar, you will receive an email with the log-on information. This reminder email includes helpful information about the webinar log-on process as well as who to contact if you are having difficulty connecting.

How can I learn more about ARCALYST® (rilonacept)?

To learn more about ARCALYST, talk to your physician, and see full Prescribing Information at ARCALYST.com/PI. You can also learn more at www.arcalyst.com.